

John R Mascola

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4930036/publications.pdf>

Version: 2024-02-01

384
papers

73,440
citations

518

131
h-index

924

247
g-index

411
all docs

411
docs citations

411
times ranked

46304
citing authors

#	ARTICLE	IF	CITATIONS
1	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , 2022, 14, eabj7125.	5.8	93
2	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	13.5	64
3	Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention. <i>Journal of Infectious Diseases</i> , 2022, 226, 510-520.	1.9	13
4	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. <i>New England Journal of Medicine</i> , 2022, 386, 1088-1091.	13.9	338
5	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. <i>Cell Reports</i> , 2022, 38, 110199.	2.9	19
6	Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 383-391.	15.2	65
7	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18.	13.5	179
8	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. <i>Science</i> , 2022, 376, eabn8897.	6.0	119
9	Development of Neutralization Breadth against Diverse HIV-1 by Increasing Ab-Ag Interface on V2. <i>Advanced Science</i> , 2022, , 2200063.	5.6	3
10	Antigenic analysis of the HIV-1 envelope trimer implies small differences between structural states 1 and 2. <i>Journal of Biological Chemistry</i> , 2022, 298, 101819.	1.6	9
11	Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. <i>Nature Medicine</i> , 2022, 28, 1022-1030.	15.2	34
12	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 39, 110812.	2.9	287
13	Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1210-1220.	4.6	15
14	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. <i>Nature Medicine</i> , 2022, 28, 1288-1296.	15.2	44
15	Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. <i>PLoS ONE</i> , 2022, 17, e0268767.	1.1	18
16	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. <i>EClinicalMedicine</i> , 2022, 48, 101477.	3.2	13
17	Elicitation of pneumovirus-specific B cell responses by a prefusion-stabilized respiratory syncytial virus F subunit vaccine. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	7
18	Broad coverage of neutralization-resistant SIV strains by second-generation SIV-specific antibodies targeting the region involved in binding CD4. <i>PLoS Pathogens</i> , 2022, 18, e1010574.	2.1	6

#	ARTICLE	IF	CITATIONS
19	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. <i>Structure</i> , 2022, 30, 1233-1244.e7.	1.6	13
20	Broadly neutralizing antibodies target the coronavirus fusion peptide. <i>Science</i> , 2022, 377, 728-735.	6.0	111
21	Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. <i>New England Journal of Medicine</i> , 2021, 384, 80-82.	13.9	665
22	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. <i>Science</i> , 2021, 371, .	6.0	49
23	Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 184-192.	2.3	6
24	Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. <i>Vaccines</i> , 2021, 9, 73.	2.1	24
25	A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. <i>MAbs</i> , 2021, 13, 1946918.	2.6	11
26	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 403-416.	13.9	7,910
27	Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials. <i>EBioMedicine</i> , 2021, 64, 103203.	2.7	14
28	Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	49
29	Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. <i>New England Journal of Medicine</i> , 2021, 384, 1003-1014.	13.9	270
30	Quadrivalent influenza nanoparticle vaccines induce broad protection. <i>Nature</i> , 2021, 592, 623-628.	13.7	180
31	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. <i>Nature</i> , 2021, 593, 130-135.	13.7	1,904
32	The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	347
33	Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. <i>Immunity</i> , 2021, 54, 769-780.e6.	6.6	37
34	SARS-CoV-2 Viral Variantsâ€”Tackling a Moving Target. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1261.	3.8	165
35	Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1â€”Exposed Newborn Infants. <i>Journal of Infectious Diseases</i> , 2021, 224, 1916-1924.	1.9	27
36	Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 2259-2261.	13.9	603

#	ARTICLE	IF	CITATIONS
37	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , 2021, 373, .	6.0	174
38	Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009738.	2.1	7
39	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , 2021, 184, 4203-4219.e32.	13.5	228
40	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. <i>Immunity</i> , 2021, 54, 1636-1651.	6.6	165
41	Blocking $\alpha 4 \beta 7$ integrin delays viral rebound in SHIV _{SF162P3} -infected macaques treated with anti-HIV broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	11
42	A Monoclonal Antibody for Malaria Prevention. <i>New England Journal of Medicine</i> , 2021, 385, 803-814.	13.9	95
43	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj5413.	5.8	79
44	Durability of mRNA-1273 vaccineâ€‘induced antibodies against SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 1372-1377.	6.0	459
45	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. <i>Science</i> , 2021, 373, eabj0299.	6.0	244
46	Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	20
47	Structurally related but genetically unrelated antibody lineages converge on an immunodominant HIV-1 Env neutralizing determinant following trimer immunization. <i>PLoS Pathogens</i> , 2021, 17, e1009543.	2.1	5
48	Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	1
49	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. <i>New England Journal of Medicine</i> , 2021, 385, 1774-1785.	13.9	402
50	SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. <i>Journal of Biological Chemistry</i> , 2021, 297, 101127.	1.6	9
51	Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1111-1120.	5.2	38
52	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccineâ€‘boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.	6.0	83
53	A multiclade envâ€‘gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. <i>Nature Medicine</i> , 2021, 27, 2234-2245.	15.2	80
54	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 772864.	2.2	21

#	ARTICLE	IF	CITATIONS
55	Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. <i>Journal of Infectious Diseases</i> , 2020, 222, 628-636.	1.9	38
56	Novel vaccine technologies for the 21st century. <i>Nature Reviews Immunology</i> , 2020, 20, 87-88.	10.6	103
57	Extensive dissemination and intraclonal maturation of HIV Env vaccine-induced B cell responses. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	23
58	Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. <i>Nature Communications</i> , 2020, 11, 70.	5.8	37
59	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , 2020, 586, 567-571.	13.7	1,153
60	Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. <i>Cell Reports</i> , 2020, 33, 108322.	2.9	59
61	Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 18754-18763.	3.3	53
62	An mRNA Vaccine against SARS-CoV-2 – Preliminary Report. <i>New England Journal of Medicine</i> , 2020, 383, 1920-1931.	13.9	2,719
63	Development of a potent Zika virus vaccine using self-amplifying messenger RNA. <i>Science Advances</i> , 2020, 6, eaba5068.	4.7	50
64	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020, 383, 1544-1555.	13.9	936
65	Immune Monitoring Reveals Fusion Peptide Priming to Imprint Cross-Clade HIV-Neutralizing Responses with a Characteristic Early B Cell Signature. <i>Cell Reports</i> , 2020, 32, 107981.	2.9	15
66	Virus-Like Particle Based Vaccines Elicit Neutralizing Antibodies against the HIV-1 Fusion Peptide. <i>Vaccines</i> , 2020, 8, 765.	2.1	12
67	A strategic approach to COVID-19 vaccine R&D. <i>Science</i> , 2020, 368, 948-950.	6.0	419
68	Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development. <i>Frontiers in Immunology</i> , 2020, 11, 842.	2.2	36
69	Monoclonal Antibodies for Prevention and Treatment of COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 131.	3.8	237
70	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	30
71	VRC34-Antibody Lineage Development Reveals How a Required Rare Mutation Shapes the Maturation of a Broad HIV-Neutralizing Lineage. <i>Cell Host and Microbe</i> , 2020, 27, 531-543.e6.	5.1	23
72	Immune checkpoint modulation enhances HIV-1 antibody induction. <i>Nature Communications</i> , 2020, 11, 948.	5.8	27

#	ARTICLE	IF	CITATIONS
73	Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials. <i>PLoS Computational Biology</i> , 2020, 16, e1007626.	1.5	20
74	HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice. <i>Journal of Immunology</i> , 2020, 204, 1543-1561.	0.4	4
75	Next-generation influenza vaccines: opportunities and challenges. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 239-252.	21.5	192
76	Structure of Super-Potent Antibody CAP256-VRC26.25 in Complex with HIV-1 Envelope Reveals a Combined Mode of Trimer-Apex Recognition. <i>Cell Reports</i> , 2020, 31, 107488.	2.9	53
77	Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1369.	3.8	68
78	Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial. <i>BMJ Open</i> , 2020, 10, e042247.	0.8	25
79	Title is missing!, 2020, 16, e1007626.		0
80	Title is missing!, 2020, 16, e1007626.		0
81	Title is missing!, 2020, 16, e1007626.		0
82	Title is missing!, 2020, 16, e1007626.		0
83	A proof of concept for structure-based vaccine design targeting RSV in humans. <i>Science</i> , 2019, 365, 505-509.	6.0	207
84	Delayed vaginal SHIV infection in VRC01 and anti- β 27 treated rhesus macaques. <i>PLoS Pathogens</i> , 2019, 15, e1007776.	2.1	16
85	Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization. <i>Cell</i> , 2019, 178, 567-584.e19.	13.5	106
86	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. <i>Nature Communications</i> , 2019, 10, 2898.	5.8	35
87	Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial. <i>BMJ Open</i> , 2019, 9, e030283.	0.8	12
88	Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates. <i>Scientific Reports</i> , 2019, 9, 14696.	1.6	30
89	Multiple roles for HIV broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	144
90	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. <i>Cell Host and Microbe</i> , 2019, 26, 336-346.e3.	5.1	88

#	ARTICLE	IF	CITATIONS
91	Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. <i>Lancet HIV</i> , 2019, 6, e667-e679.	2.1	67
92	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1008026.	2.1	56
93	Comparison of adjuvants to optimize influenza neutralizing antibody responses. <i>Vaccine</i> , 2019, 37, 6208-6220.	1.7	16
94	Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. <i>Lancet</i> , 2019, 393, 889-898.	6.3	99
95	Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. <i>Immunity</i> , 2019, 50, 1513-1529.e9.	6.6	85
96	A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	42
97	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. <i>PLoS ONE</i> , 2019, 14, e0215163.	1.1	41
98	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet HIV</i> , 2019, 6, e297-e306.	2.1	73
99	Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages. <i>MBio</i> , 2019, 10, .	1.8	88
100	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. <i>Immunity</i> , 2019, 50, 677-691.e13.	6.6	77
101	Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. <i>Nature Immunology</i> , 2019, 20, 362-372.	7.0	211
102	Improvement of antibody functionality by structure-guided paratope engraftment. <i>Nature Communications</i> , 2019, 10, 721.	5.8	27
103	Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability. <i>Immunity</i> , 2019, 51, 915-929.e7.	6.6	111
104	Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry. <i>Nature Communications</i> , 2019, 10, 47.	5.8	50
105	Structural Survey of Broadly Neutralizing Antibodies Targeting the HIV-1 Env Trimer Delineates Epitope Categories and Characteristics of Recognition. <i>Structure</i> , 2019, 27, 196-206.e6.	1.6	69
106	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. <i>Cell Host and Microbe</i> , 2019, 25, 59-72.e8.	5.1	124
107	Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk. <i>Journal of Clinical Investigation</i> , 2019, 129, 4838-4849.	3.9	95
108	Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B. <i>Pathogens and Immunity</i> , 2019, 4, 294.	1.4	26

#	ARTICLE	IF	CITATIONS
109	Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. <i>Journal of Virology</i> , 2018, 92, .	1.5	155
110	Rational design of a trisppecific antibody targeting the HIV-1 Env with elevated anti-viral activity. <i>Nature Communications</i> , 2018, 9, 877.	5.8	65
111	Two-Component Ferritin Nanoparticles for Multimerization of Diverse Trimeric Antigens. <i>ACS Infectious Diseases</i> , 2018, 4, 788-796.	1.8	65
112	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. <i>Cell Reports</i> , 2018, 22, 1798-1809.	2.9	52
113	Functional interrogation and mining of natively paired human VH:VL antibody repertoires. <i>Nature Biotechnology</i> , 2018, 36, 152-155.	9.4	109
114	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 2116-2127.	1.4	17
115	Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection. <i>Journal of Infectious Diseases</i> , 2018, 217, 1530-1534.	1.9	6
116	Novel Vaccine Technologies. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1431.	3.8	73
117	Is It Possible to Develop a "Universal" Influenza Virus Vaccine?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a029413.	2.3	34
118	Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. <i>Lancet, The</i> , 2018, 391, 552-562.	6.3	235
119	Structure-based design of a quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1-4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12265-12270.	3.3	70
120	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2018, 14, e1007431.	2.1	36
121	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. <i>Immunity</i> , 2018, 49, 1162-1174.e8.	6.6	61
122	Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. <i>PLoS Pathogens</i> , 2018, 14, e1007395.	2.1	37
123	HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure. <i>Immunity</i> , 2018, 48, 855-871.	6.6	277
124	Glycoengineering HIV-1 Env creates "supercharged" and "hybrid" glycans to increase neutralizing antibody potency, breadth and saturation. <i>PLoS Pathogens</i> , 2018, 14, e1007024.	2.1	22
125	Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV. <i>PLoS Pathogens</i> , 2018, 14, e1007159.	2.1	46
126	Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. <i>Nature Medicine</i> , 2018, 24, 857-867.	15.2	256

#	ARTICLE	IF	CITATIONS
127	Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults. <i>PLoS Medicine</i> , 2018, 15, e1002493.	3.9	174
128	Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. <i>PLoS Pathogens</i> , 2018, 14, e1006860.	2.1	68
129	Accumulation of follicular CD8+ T cells in pathogenic SIV infection. <i>Journal of Clinical Investigation</i> , 2018, 128, 2089-2103.	3.9	43
130	Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors. <i>PLoS ONE</i> , 2018, 13, e0193773.	1.1	24
131	Chimpanzee Adenovirus Vector Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 928-938.	13.9	243
132	Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	135
133	Use of broadly neutralizing antibodies for <sc>HIV</sc> prevention. <i>Immunological Reviews</i> , 2017, 275, 296-312.	2.8	131
134	The quest for an antibody-based <sc>HIV</sc> vaccine. <i>Immunological Reviews</i> , 2017, 275, 5-10.	2.8	91
135	Antibodyomics: bioinformatics technologies for understanding B cell immunity to <sc>HIV</sc>. <i>Immunological Reviews</i> , 2017, 275, 108-128.	2.8	32
136	Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity. <i>Journal of Virology</i> , 2017, 91, .	1.5	81
137	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017, 2, .	5.6	119
138	Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach. <i>Immunity</i> , 2017, 46, 804-817.e7.	6.6	107
139	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. <i>Cell Reports</i> , 2017, 19, 719-732.	2.9	160
140	Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity. <i>Journal of Biological Chemistry</i> , 2017, 292, 10197-10219.	1.6	29
141	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. <i>Journal of Virology</i> , 2017, 91, .	1.5	40
142	Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	212
143	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	81
144	Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. <i>Nature Chemical Biology</i> , 2017, 13, 1115-1122.	3.9	110

#	ARTICLE	IF	CITATIONS
145	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. <i>Science</i> , 2017, 358, 85-90.	6.0	225
146	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	106
147	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	87
148	Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8614-8619.	3.3	42
149	Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. <i>Journal of Virology</i> , 2017, 91, .	1.5	38
150	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. <i>Cell Reports</i> , 2017, 21, 3681-3690.	2.9	97
151	Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials. <i>Statistical Communications in Infectious Diseases</i> , 2017, 9, .	0.2	62
152	Gene-Specific Substitution Profiles Describe the Types and Frequencies of Amino Acid Changes during Antibody Somatic Hypermutation. <i>Frontiers in Immunology</i> , 2017, 8, 537.	2.2	82
153	Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting. <i>PLoS Pathogens</i> , 2017, 13, e1006148.	2.1	51
154	Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. <i>PLoS Medicine</i> , 2017, 14, e1002435.	3.9	104
155	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. <i>Nature Communications</i> , 2017, 8, 1732.	5.8	76
156	Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120. <i>PLoS ONE</i> , 2017, 12, e0185959.	1.1	27
157	Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus. <i>PLoS ONE</i> , 2017, 12, e0186854.	1.1	42
158	Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. <i>PLoS Pathogens</i> , 2017, 13, e1006074.	2.1	33
159	SONAR: A High-Throughput Pipeline for Inferring Antibody Ontogenies from Longitudinal Sequencing of B Cell Transcripts. <i>Frontiers in Immunology</i> , 2016, 7, 372.	2.2	67
160	Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection. <i>PLoS Computational Biology</i> , 2016, 12, e1004940.	1.5	35
161	Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. <i>PLoS Pathogens</i> , 2016, 12, e1005520.	2.1	150
162	Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. <i>PLoS Pathogens</i> , 2016, 12, e1005537.	2.1	51

#	ARTICLE	IF	CITATIONS
163	Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. <i>Immunity</i> , 2016, 44, 939-950.	6.6	85
164	HIV Immunology Goes Out On a Limb. <i>Immunity</i> , 2016, 44, 1088-1090.	6.6	2
165	Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G. <i>Cell</i> , 2016, 165, 813-826.	13.5	379
166	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. <i>Nature</i> , 2016, 533, 105-109.	13.7	281
167	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. <i>Journal of Virology</i> , 2016, 90, 5899-5914.	1.5	62
168	Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. <i>Science</i> , 2016, 352, 828-833.	6.0	310
169	Thermoresponsive Polymer Nanoparticles Co-deliver RSV F Trimers with a TLR-7/8 Adjuvant. <i>Bioconjugate Chemistry</i> , 2016, 27, 2372-2385.	1.8	44
170	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. <i>Cell</i> , 2016, 166, 1471-1484.e18.	13.5	198
171	Rapid development of a DNA vaccine for Zika virus. <i>Science</i> , 2016, 354, 237-240.	6.0	348
172	Multiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding. <i>Journal of Virology</i> , 2016, 90, 10574-10586.	1.5	35
173	Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies. <i>Structure</i> , 2016, 24, 1346-1357.	1.6	35
174	Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 811-820.	3.6	110
175	Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype. <i>Cell Reports</i> , 2016, 16, 1485-1491.	2.9	190
176	Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. <i>Cell</i> , 2016, 166, 609-623.	13.5	270
177	Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. <i>Immunity</i> , 2016, 45, 1108-1121.	6.6	304
178	Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. <i>New England Journal of Medicine</i> , 2016, 375, 2037-2050.	13.9	391
179	An HIV-1 Env "Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes. <i>Journal of Immunology</i> , 2016, 197, 3982-3998.	0.4	17
180	Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. <i>Nature Medicine</i> , 2016, 22, 1456-1464.	15.2	271

#	ARTICLE	IF	CITATIONS
181	Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. <i>Nature Medicine</i> , 2016, 22, 362-368.	15.2	163
182	High-Resolution Longitudinal Study of HIV-1 Env Vaccine-elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence. <i>Journal of Immunology</i> , 2016, 196, 3729-3743.	0.4	26
183	Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. <i>Science</i> , 2016, 351, 1339-1342.	6.0	370
184	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016, 165, 449-463.	13.5	305
185	Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody. <i>Journal of Virology</i> , 2016, 90, 2740-2755.	1.5	58
186	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 81-90.	3.6	162
187	In vitro reconstitution of B cell receptor-antigen interactions to evaluate potential vaccine candidates. <i>Nature Protocols</i> , 2016, 11, 193-213.	5.5	51
188	Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. <i>Journal of Virology</i> , 2016, 90, 1321-1332.	1.5	68
189	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , 2016, 90, 76-91.	1.5	205
190	Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. <i>PLoS ONE</i> , 2016, 11, e0157409.	1.1	44
191	A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial Virus. <i>PLoS ONE</i> , 2015, 10, e0128779.	1.1	38
192	Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env. <i>Journal of Virology</i> , 2015, 89, 5318-5329.	1.5	125
193	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. <i>Cell</i> , 2015, 161, 1280-1292.	13.5	305
194	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. <i>Science Translational Medicine</i> , 2015, 7, 319ra206.	5.8	390
195	Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. <i>Lancet, The</i> , 2015, 385, 1545-1554.	6.3	109
196	HIV-1 Fitness Cost Associated with Escape from the VRC01 Class of CD4 Binding Site Neutralizing Antibodies. <i>Journal of Virology</i> , 2015, 89, 4201-4213.	1.5	121
197	Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes. <i>Journal of Virology</i> , 2015, 89, 2659-2671.	1.5	123
198	Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site. <i>PLoS Pathogens</i> , 2015, 11, e1004932.	2.1	141

#	ARTICLE	IF	CITATIONS
199	Evaluation of candidate vaccine approaches for MERS-CoV. <i>Nature Communications</i> , 2015, 6, 7712.	5.8	258
200	Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015, 349, aab1253.	6.0	191
201	Quality and quantity of T _{FH} cells are critical for broad antibody development in SHIV _{AD8} infection. <i>Science Translational Medicine</i> , 2015, 7, 298ra120.	5.8	119
202	The modern era of HIV-1 vaccine development. <i>Science</i> , 2015, 349, 139-140.	6.0	36
203	Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. <i>Nature Structural and Molecular Biology</i> , 2015, 22, 522-531.	3.6	333
204	Analysis of immunoglobulin transcripts and hypermutation following SHIVAD8 infection and protein-plus-adjuvant immunization. <i>Nature Communications</i> , 2015, 6, 6565.	5.8	77
205	Diverse Antibody Genetic and Recognition Properties Revealed following HIV-1 Envelope Glycoprotein Immunization. <i>Journal of Immunology</i> , 2015, 194, 5903-5914.	0.4	24
206	Antibody responses to envelope glycoproteins in HIV-1 infection. <i>Nature Immunology</i> , 2015, 16, 571-576.	7.0	364
207	Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. <i>Cell</i> , 2015, 161, 470-485.	13.5	226
208	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015, 89, 5895-5903.	1.5	92
209	Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development. <i>Vaccine</i> , 2015, 33, 7344-7351.	1.7	16
210	Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. <i>Cell</i> , 2015, 162, 1090-1100.	13.5	278
211	Activation and lysis of human CD4 cells latently infected with HIV-1. <i>Nature Communications</i> , 2015, 6, 8447.	5.8	88
212	Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015, 89, 8334-8345.	1.5	100
213	Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. <i>Nature Medicine</i> , 2015, 21, 1332-1336.	15.2	215
214	Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. <i>Nature Medicine</i> , 2015, 21, 1065-1070.	15.2	567
215	Editorial overview: Vaccines: Vaccines for cancer and infectious diseases. <i>Current Opinion in Immunology</i> , 2015, 35, v-vii.	2.4	1
216	Neutralization Properties of Simian Immunodeficiency Viruses Infecting Chimpanzees and Gorillas. <i>MBio</i> , 2015, 6, .	1.8	25

#	ARTICLE	IF	CITATIONS
217	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015, 18, 354-362.	5.1	66
218	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. <i>Science Translational Medicine</i> , 2014, 6, 243ra88.	5.8	222
219	HIV-1 Receptor Binding Site-Directed Antibodies Using a VH1-2 Gene Segment Orthologue Are Activated by Env Trimer Immunization. <i>PLoS Pathogens</i> , 2014, 10, e1004337.	2.1	23
220	Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6. <i>Journal of Virology</i> , 2014, 88, 2426-2441.	1.5	41
221	Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. <i>Journal of Immunological Methods</i> , 2014, 409, 131-146.	0.6	435
222	Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline. <i>Journal of Immunology</i> , 2014, 192, 1100-1106.	0.4	86
223	Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. <i>Nature</i> , 2014, 509, 55-62.	13.7	681
224	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. <i>Nature</i> , 2014, 505, 502-508.	13.7	140
225	Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. <i>Journal of Experimental Medicine</i> , 2014, 211, 2061-2074.	4.2	297
226	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i> . <i>Journal of Virology</i> , 2014, 88, 12669-12682.	1.5	248
227	Global Panel of HIV-1 Env Reference Strains for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. <i>Journal of Virology</i> , 2014, 88, 2489-2507.	1.5	274
228	Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies. <i>Cell Host and Microbe</i> , 2014, 16, 304-313.	5.1	137
229	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. <i>Cell</i> , 2014, 158, 481-491.	13.5	266
230	Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. <i>Nature</i> , 2014, 514, 642-645.	13.7	308
231	Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies. <i>Journal of Virology</i> , 2014, 88, 12623-12643.	1.5	75
232	Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. <i>Lancet, The</i> , 2014, 384, 2046-2052.	6.3	206
233	Single-Cell and Deep Sequencing of IgG-Switched Macaque B Cells Reveal a Diverse Ig Repertoire following Immunization. <i>Journal of Immunology</i> , 2014, 192, 3637-3644.	0.4	55
234	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. <i>Nature</i> , 2014, 514, 455-461.	13.7	702

#	ARTICLE	IF	CITATIONS
235	Hyperglycosylated Stable Core Immunogens Designed To Present the CD4 Binding Site Are Preferentially Recognized by Broadly Neutralizing Antibodies. <i>Journal of Virology</i> , 2014, 88, 14002-14016.	1.5	43
236	Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. <i>Nature Medicine</i> , 2014, 20, 1126-1129.	15.2	311
237	Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. <i>Nature</i> , 2014, 515, 138-142.	13.7	400
238	Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. <i>Aids</i> , 2014, 28, 163-169.	1.0	334
239	An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. <i>Journal of Clinical Investigation</i> , 2014, 124, 1835-1843.	3.9	93
240	Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies. <i>Immunity</i> , 2013, 39, 245-258.	6.6	332
241	Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. <i>Nature Reviews Immunology</i> , 2013, 13, 693-701.	10.6	302
242	Structural Basis for Highly Effective HIV-1 Neutralization by CD4-Mimetic Mini-proteins Revealed by 1.5 Å Resolution Cryo-EM of a gp120-Mimetic Mini-protein Complex. <i>Structure</i> , 2013, 21, 1018-1029.	1.6	29
243	Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. <i>New England Journal of Medicine</i> , 2013, 369, 2083-2092.	13.9	518
244	Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04. <i>Journal of Virology</i> , 2013, 87, 2294-2306.	1.5	34
245	Broadly neutralizing antibodies: understanding nature's pathways. <i>Immunological Reviews</i> , 2013, 254, 225-244.	2.8	442
246	Isolation of human monoclonal antibodies from peripheral blood B cells. <i>Nature Protocols</i> , 2013, 8, 1907-1915.	5.5	167
247	Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-ray and Thermodynamic Characterization. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 338-343.	1.3	56
248	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. <i>Nature</i> , 2013, 496, 469-476.	13.7	961
249	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. <i>Immunity</i> , 2013, 38, 176-186.	6.6	374
250	Mining the antibodyome for HIV-1 neutralizing antibodies with next-generation sequencing and phylogenetic pairing of heavy/light chains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6470-6475.	3.3	142
251	Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization. <i>Science</i> , 2013, 340, 751-756.	6.0	213
252	Structural basis for diverse N-glycan recognition by HIV-1 neutralizing V1-directed antibody PG16. <i>Nature Structural and Molecular Biology</i> , 2013, 20, 804-813.	3.6	257

#	ARTICLE	IF	CITATIONS
253	De novo identification of VRC01 class HIV-1 neutralizing antibodies by next-generation sequencing of B-cell transcripts. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4088-97.	3.3	105
254	Residue-Level Prediction of HIV-1 Antibody Epitopes Based on Neutralization of Diverse Viral Strains. Journal of Virology, 2013, 87, 10047-10058.	1.5	64
255	Robust Neutralizing Antibodies Elicited by HIV-1 JRFL Envelope Glycoprotein Trimers in Nonhuman Primates. Journal of Virology, 2013, 87, 13239-13251.	1.5	63
256	Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDS VAX HIV-1 Vaccine Efficacy Trial. PLoS ONE, 2013, 8, e53629.	1.1	165
257	N332-Directed Broadly Neutralizing Antibodies Use Diverse Modes of HIV-1 Recognition: Inferences from Heavy-Light Chain Complementations of Function. PLoS ONE, 2013, 8, e55701.	1.1	38
258	DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial. PLoS ONE, 2013, 8, e59340.	1.1	71
259	Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial. PLoS ONE, 2013, 8, e75665.	1.1	214
260	PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4. Journal of Virology, 2012, 86, 4394-4403.	1.5	109
261	BlyS-Mediated Modulation of Naïve B Cell Subsets Impacts HIV Env-Induced Antibody Responses. Journal of Immunology, 2012, 188, 6018-6026.	0.4	34
262	Most rhesus macaques infected with the CCR5-tropic SHIV _{AD8} generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19769-19774.	3.3	72
263	A Short Segment of the HIV-1 gp120 V1/V2 Region Is a Major Determinant of Resistance to V1/V2 Neutralizing Antibodies. Journal of Virology, 2012, 86, 8319-8323.	1.5	76
264	HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes. Journal of Virology, 2012, 86, 3393-3397.	1.5	71
265	Biochemically Defined HIV-1 Envelope Glycoprotein Variant Immunogens Display Differential Binding and Neutralizing Specificities to the CD4-binding Site. Journal of Biological Chemistry, 2012, 287, 5673-5686.	1.6	50
266	The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. AIDS Research and Human Retroviruses, 2012, 28, 1444-1457.	0.5	191
267	Anti-HIV B Cell Lines as Candidate Vaccine Biosensors. Journal of Immunology, 2012, 189, 4816-4824.	0.4	57
268	Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies. Immunity, 2012, 37, 412-425.	6.6	417
269	Gene-Based Vaccination with a Mismatched Envelope Protects against Simian Immunodeficiency Virus Infection in Nonhuman Primates. Journal of Virology, 2012, 86, 7760-7770.	1.5	31
270	HIV-1 Neutralizing Antibodies Display Dual Recognition of the Primary and Coreceptor Binding Sites and Preferential Binding to Fully Cleaved Envelope Glycoproteins. Journal of Virology, 2012, 86, 11231-11241.	1.5	61

#	ARTICLE	IF	CITATIONS
271	Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site. <i>Journal of Virology</i> , 2012, 86, 5844-5856.	1.5	75
272	Pathogenicity and Mucosal Transmissibility of the R5-Tropic Simian/Human Immunodeficiency Virus SHIV _{AD8} in Rhesus Macaques: Implications for Use in Vaccine Studies. <i>Journal of Virology</i> , 2012, 86, 8516-8526.	1.5	47
273	Antibody-Dependent Cellular Cytotoxicity against Primary HIV-Infected CD4 ⁺ T Cells Is Directly Associated with the Magnitude of Surface IgG Binding. <i>Journal of Virology</i> , 2012, 86, 8672-8680.	1.5	97
274	Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. <i>Nature</i> , 2012, 491, 406-412.	13.7	753
275	The Development of CD4 Binding Site Antibodies during HIV-1 Infection. <i>Journal of Virology</i> , 2012, 86, 7588-7595.	1.5	123
276	Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design. <i>Journal of Virology</i> , 2012, 86, 4688-4692.	1.5	159
277	Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5663-5668.	3.3	222
278	High-Resolution Definition of Vaccine-Elicited B Cell Responses Against the HIV Primary Receptor Binding Site. <i>Science Translational Medicine</i> , 2012, 4, 142ra96.	5.8	108
279	Somatic populations of PGT135 ¹³⁷ HIV-1-neutralizing antibodies identified by 454 pyrosequencing and bioinformatic. <i>Frontiers in Microbiology</i> , 2012, 3, 315.	1.5	70
280	The changing face of HIV vaccine research. <i>Journal of the International AIDS Society</i> , 2012, 15, 17407.	1.2	47
281	Structure-Based Design, Synthesis, and Characterization of Dual Hotspot Small-Molecule HIV-1 Entry Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4382-4396.	2.9	90
282	A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial. <i>Journal of Infectious Diseases</i> , 2011, 203, 1396-1404.	1.9	138
283	Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01. <i>Journal of Virology</i> , 2011, 85, 8954-8967.	1.5	209
284	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. <i>Journal of Virology</i> , 2011, 85, 9998-10009.	1.5	393
285	Polyclonal B Cell Responses to Conserved Neutralization Epitopes in a Subset of HIV-1-Infected Individuals. <i>Journal of Virology</i> , 2011, 85, 11502-11519.	1.5	168
286	Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. <i>Science</i> , 2011, 333, 1593-1602.	6.0	788
287	DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 916-924.	4.6	174
288	Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1. <i>Journal of Virology</i> , 2011, 85, 2524-2535.	1.5	46

#	ARTICLE	IF	CITATIONS
289	HIV Type 1 Env Precursor Cleavage State Affects Recognition by Both Neutralizing and Nonneutralizing gp41 Antibodies. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 877-887.	0.5	57
290	Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies. <i>Journal of Virology</i> , 2011, 85, 11401-11408.	1.5	80
291	Antibody-Dependent Cell-Mediated Cytotoxicity in Simian Immunodeficiency Virus-Infected Rhesus Monkeys. <i>Journal of Virology</i> , 2011, 85, 6906-6912.	1.5	67
292	Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011, 1, a007278-a007278.	2.9	135
293	The <i>TRIM5</i> Gene Modulates Penile Mucosal Acquisition of Simian Immunodeficiency Virus in Rhesus Monkeys. <i>Journal of Virology</i> , 2011, 85, 10389-10398.	1.5	43
294	Antibody-Dependent Cell-Mediated Viral Inhibition Emerges after Simian Immunodeficiency Virus SIVmac251 Infection of Rhesus Monkeys Coincident with gp140-Binding Antibodies and Is Effective against Neutralization-Resistant Viruses. <i>Journal of Virology</i> , 2011, 85, 5465-5475.	1.5	47
295	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. <i>Nature</i> , 2011, 480, 336-343.	13.7	794
296	Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies. <i>Journal of Virology</i> , 2011, 85, 4578-4585.	1.5	43
297	Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. <i>Science Translational Medicine</i> , 2011, 3, 81ra36.	5.8	179
298	Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses. <i>PLoS ONE</i> , 2010, 5, e9015.	1.1	125
299	Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. <i>Journal of Experimental Medicine</i> , 2010, 207, 2003-2017.	4.2	106
300	Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables. <i>Journal of Virology</i> , 2010, 84, 1631-1636.	1.5	304
301	Influence of Novel CD4 Binding-Defective HIV-1 Envelope Glycoprotein Immunogens on Neutralizing Antibody and T-Cell Responses in Nonhuman Primates. <i>Journal of Virology</i> , 2010, 84, 1683-1695.	1.5	44
302	Relationship between Antibody 2F5 Neutralization of HIV-1 and Hydrophobicity of Its Heavy Chain Third Complementarity-Determining Region. <i>Journal of Virology</i> , 2010, 84, 2955-2962.	1.5	106
303	The Role of Antibodies in HIV Vaccines. <i>Annual Review of Immunology</i> , 2010, 28, 413-444.	9.5	356
304	Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01. <i>Science</i> , 2010, 329, 811-817.	6.0	1,050
305	Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. <i>Science</i> , 2010, 329, 856-861.	6.0	1,600
306	Crystal Structure of PG16 and Chimeric Dissection with Somatic Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1. <i>Journal of Virology</i> , 2010, 84, 8098-8110.	1.5	209

#	ARTICLE	IF	CITATIONS
307	Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies. <i>Journal of Virology</i> , 2010, 84, 1439-1452.	1.5	589
308	Human Immunodeficiency Virus Type 1 Env Trimer Immunization of Macaques and Impact of Priming with Viral Vector or Stabilized Core Protein. <i>Journal of Virology</i> , 2009, 83, 540-551.	1.5	54
309	Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment. <i>Journal of Virology</i> , 2009, 83, 10892-10907.	1.5	86
310	Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors. <i>Journal of Virology</i> , 2009, 83, 8925-8937.	1.5	170
311	Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals. <i>Journal of Virology</i> , 2009, 83, 1045-1059.	1.5	238
312	Structure-Based Stabilization of HIV-1 gp120 Enhances Humoral Immune Responses to the Induced Co-Receptor Binding Site. <i>PLoS Pathogens</i> , 2009, 5, e1000445.	2.1	113
313	Enhanced Exposure of the CD4-Binding Site to Neutralizing Antibodies by Structural Design of a Membrane-Anchored Human Immunodeficiency Virus Type 1 gp120 Domain. <i>Journal of Virology</i> , 2009, 83, 5077-5086.	1.5	43
314	Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. <i>Journal of Experimental Medicine</i> , 2009, 206, 1117-1134.	4.2	295
315	Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies. <i>Journal of Virology</i> , 2009, 83, 188-199.	1.5	297
316	Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region. <i>Journal of Virology</i> , 2009, 83, 11265-11274.	1.5	93
317	A method for identification of HIV gp140 binding memory B cells in human blood. <i>Journal of Immunological Methods</i> , 2009, 343, 65-67.	0.6	204
318	Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. <i>Nature</i> , 2009, 458, 636-640.	13.7	806
319	Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?. <i>Nature Medicine</i> , 2009, 15, 866-870.	15.2	390
320	Mining the B Cell Repertoire for Broadly Neutralizing Monoclonal Antibodies to HIV-1. <i>Cell Host and Microbe</i> , 2009, 6, 292-294.	5.1	22
321	Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120. <i>Science</i> , 2009, 326, 1123-1127.	6.0	271
322	Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 347-351.	1.5	47
323	A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. <i>Vaccine</i> , 2008, 26, 6338-6343.	1.7	230
324	Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C. <i>Journal of Virology</i> , 2008, 82, 11651-11668.	1.5	337

#	ARTICLE	IF	CITATIONS
325	Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody That Recognizes a Novel Conformational Epitope on gp41 and Lacks Reactivity against Self-Antigens. <i>Journal of Virology</i> , 2008, 82, 6869-6879.	1.5	41
326	B Cell Recognition of the Conserved HIV-1 Co-Receptor Binding Site Is Altered by Endogenous Primate CD4. <i>PLoS Pathogens</i> , 2008, 4, e1000171.	2.1	57
327	No Evidence for Consistent Virus-Specific Immunity in Simian Immunodeficiency Virus-Exposed, Uninfected Rhesus Monkeys. <i>Journal of Virology</i> , 2007, 81, 12368-12374.	1.5	51
328	A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial. <i>Journal of Infectious Diseases</i> , 2007, 196, 1732-1740.	1.9	175
329	Lysis of Human Immunodeficiency Virus Type 1 by a Specific Secreted Human Phospholipase A 2. <i>Journal of Virology</i> , 2007, 81, 1444-1450.	1.5	37
330	Characterization of Human Immunodeficiency Virus Type 1 Monomeric and Trimeric gp120 Glycoproteins Stabilized in the CD4-Bound State: Antigenicity, Biophysics, and Immunogenicity. <i>Journal of Virology</i> , 2007, 81, 5579-5593.	1.5	101
331	Dendritic Cells Are Less Susceptible to Human Immunodeficiency Virus Type 2 (HIV-2) Infection than to HIV-1 Infection. <i>Journal of Virology</i> , 2007, 81, 13486-13498.	1.5	49
332	Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. <i>Vaccine</i> , 2007, 25, 4085-4092.	1.7	134
333	Broad HIV-1 neutralization mediated by CD4-binding site antibodies. <i>Nature Medicine</i> , 2007, 13, 1032-1034.	15.2	364
334	Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. <i>Virology</i> , 2006, 350, 34-47.	1.1	98
335	Gene transfer in humans using a conditionally replicating lentiviral vector. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 17372-17377.	3.3	452
336	Preserved CD4+ Central Memory T Cells and Survival in Vaccinated SIV-Challenged Monkeys. <i>Science</i> , 2006, 312, 1530-1533.	6.0	343
337	Virus-Specific Cellular Immune Correlates of Survival in Vaccinated Monkeys after Simian Immunodeficiency Virus Challenge. <i>Journal of Virology</i> , 2006, 80, 10950-10956.	1.5	53
338	Preservation of Functional Virus-Specific Memory CD8+ T Lymphocytes in Vaccinated, Simian Human Immunodeficiency Virus-Infected Rhesus Monkeys. <i>Journal of Immunology</i> , 2006, 176, 5338-5345.	0.4	34
339	Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys. <i>Journal of Virology</i> , 2005, 79, 2956-2963.	1.5	120
340	A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates. <i>Journal of Virology</i> , 2005, 79, 8828-8834.	1.5	162
341	Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines. <i>Journal of Virology</i> , 2005, 79, 10103-10107.	1.5	233
342	Dysfunction of Simian Immunodeficiency Virus/Simian Human Immunodeficiency Virus-Induced IL-2 Expression by Central Memory CD4+ T Lymphocytes. <i>Journal of Immunology</i> , 2005, 174, 4753-4760.	0.4	27

#	ARTICLE	IF	CITATIONS
343	Pathogenicity of Simian-Human Immunodeficiency Virus SHIV-89.6P and SIVmac Is Attenuated in Cynomolgus Macaques and Associated with Early T-Lymphocyte Responses. <i>Journal of Virology</i> , 2005, 79, 8878-8885.	1.5	120
344	Vaccine-Elicited Memory Cytotoxic T Lymphocytes Contribute to Mamu-A*01-Associated Control of Simian/Human Immunodeficiency Virus 89.6P Replication in Rhesus Monkeys. <i>Journal of Virology</i> , 2005, 79, 4580-4588.	1.5	27
345	Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. <i>Journal of Experimental Medicine</i> , 2005, 201, 2023-2033.	4.2	183
346	Neutralizing Antibodies Elicited by Immunization of Monkeys with DNA Plasmids and Recombinant Adenoviral Vectors Expressing Human Immunodeficiency Virus Type 1 Proteins. <i>Journal of Virology</i> , 2005, 79, 771-779.	1.5	100
347	Replication-Defective Adenovirus Serotype 5 Vectors Elicit Durable Cellular and Humoral Immune Responses in Nonhuman Primates. <i>Journal of Virology</i> , 2005, 79, 6516-6522.	1.5	136
348	Differential Susceptibility to Human Immunodeficiency Virus Type 1 Infection of Myeloid and Plasmacytoid Dendritic Cells. <i>Journal of Virology</i> , 2005, 79, 8861-8869.	1.5	192
349	Biochemical and Immunogenic Characterization of Soluble Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Expressed by Semliki Forest Virus. <i>Journal of Virology</i> , 2005, 79, 10902-10914.	1.5	35
350	Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies. <i>Journal of Virology</i> , 2005, 79, 10108-10125.	1.5	1,025
351	Effects of Antibody on Viral Kinetics in Simian/Human Immunodeficiency Virus Infection: Implications for Vaccination. <i>Journal of Virology</i> , 2004, 78, 5520-5522.	1.5	23
352	Immunogenicity of Constrained Monoclonal Antibody A32-Human Immunodeficiency Virus (HIV) Env gp120 Complexes Compared to That of Recombinant HIV Type 1 gp120 Envelope Glycoproteins. <i>Journal of Virology</i> , 2004, 78, 5270-5278.	1.5	40
353	Structure and Mechanistic Analysis of the Anti-Human Immunodeficiency Virus Type 1 Antibody 2F5 in Complex with Its gp41 Epitope. <i>Journal of Virology</i> , 2004, 78, 10724-10737.	1.5	452
354	The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope. <i>Journal of Virology</i> , 2004, 78, 2394-2404.	1.5	111
355	Heterologous Envelope Immunogens Contribute to AIDS Vaccine Protection in Rhesus Monkeys. <i>Journal of Virology</i> , 2004, 78, 7490-7497.	1.5	126
356	Selective Modification of Variable Loops Alters Tropism and Enhances Immunogenicity of Human Immunodeficiency Virus Type 1 Envelope. <i>Journal of Virology</i> , 2004, 78, 4029-4036.	1.5	68
357	The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. <i>Nature</i> , 2003, 426, 853-857.	13.7	219
358	HIV-1: nature's master of disguise. <i>Nature Medicine</i> , 2003, 9, 393-394.	15.2	49
359	Specific Antibody Responses to Vaccination with Bivalent CM235/SF2 gp120: Detection of Homologous and Heterologous Neutralizing Antibody to Subtype E (CRF01.AE) HIV Type 1. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 807-816.	0.5	27
360	Cellular Immunity Elicited by Human Immunodeficiency Virus Type 1/ Simian Immunodeficiency Virus DNA Vaccination Does Not Augment the Sterile Protection Afforded by Passive Infusion of Neutralizing Antibodies. <i>Journal of Virology</i> , 2003, 77, 10348-10356.	1.5	50

#	ARTICLE	IF	CITATIONS
361	Diverse HIV-1 subtypes and clinical, laboratory and behavioral factors in a recently infected US military cohort. <i>Aids</i> , 2003, 17, 2521-2527.	1.0	64
362	Defining the Protective Antibody Response for HIV-1. <i>Current Molecular Medicine</i> , 2003, 3, 209-216.	0.6	121
363	Human Immunodeficiency Virus Type 1 Neutralization Measured by Flow Cytometric Quantitation of Single-Round Infection of Primary Human T Cells. <i>Journal of Virology</i> , 2002, 76, 4810-4821.	1.5	106
364	Elicitation of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Mucosal Compartments of Rhesus Monkeys by Systemic Vaccination. <i>Journal of Virology</i> , 2002, 76, 11484-11490.	1.5	47
365	Selective Increases in HIV-Specific Neutralizing Antibody and Partial Reconstitution of Cellular Immune Responses during Prolonged, Successful Drug Therapy of HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1021-1034.	0.5	26
366	Vaccines for the prevention of HIV-1 disease. <i>Current Opinion in Immunology</i> , 2001, 13, 489-494.	2.4	59
367	Human Dendritic Cells as Targets of Dengue Virus Infection. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2001, 6, 219-224.	0.8	149
368	Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naïve HIV-1 infected US military personnel. <i>Aids</i> , 2000, 14, 1009-1015.	1.0	103
369	Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. <i>Nature Medicine</i> , 2000, 6, 207-210.	15.2	1,237
370	Human skin Langerhans cells are targets of dengue virus infection. <i>Nature Medicine</i> , 2000, 6, 816-820.	15.2	586
371	Canarypox Virus-Induced Maturation of Dendritic Cells Is Mediated by Apoptotic Cell Death and Tumor Necrosis Factor Alpha Secretion. <i>Journal of Virology</i> , 2000, 74, 11329-11338.	1.5	108
372	Herpes Simplex Virus Vaccines— Why Don't Antibodies Protect?. <i>JAMA - Journal of the American Medical Association</i> , 1999, 282, 379.	3.8	30
373	Development of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 and Performance of an Improved AMPLICOR HIV-1 MONITOR Test with Isolates of Diverse Subtypes. <i>Journal of Clinical Microbiology</i> , 1999, 37, 2557-2563.	1.8	124
374	Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies. <i>Journal of Virology</i> , 1999, 73, 4009-4018.	1.5	725
375	Cross-Subtype Neutralizing Antibodies Induced in Baboons by a Subtype E gp120 Immunogen Based on an R5 Primary Human Immunodeficiency Virus Type 1 Envelope. <i>Journal of Virology</i> , 1999, 73, 4640-4650.	1.5	46
376	A Human Monoclonal Antibody Specific for the V3 Loop of HIV Type 1 Clade E Cross-React with Other HIV Type 1 Clades. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 213-221.	0.5	25
377	Neutralizing Antibodies from the Sera of Human Immunodeficiency Virus Type 1-Infected Individuals Bind to Monomeric gp120 and Oligomeric gp140. <i>Journal of Virology</i> , 1998, 72, 9656-9667.	1.5	36
378	Neutralizing Monoclonal Antibodies Block Human Immunodeficiency Virus Type 1 Infection of Dendritic Cells and Transmission to T Cells. <i>Journal of Virology</i> , 1998, 72, 9788-9794.	1.5	80

#	ARTICLE	IF	CITATIONS
379	Exclusive and Persistent Use of the Entry Coreceptor CXCR4 by Human Immunodeficiency Virus Type 1 from a Subject Homozygous for <i>CCR5</i> ^{Δ32} . <i>Journal of Virology</i> , 1998, 72, 6040-6047.	1.5	163
380	The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. <i>Nature Medicine</i> , 1997, 3, 338-340.	15.2	480
381	Human Immunodeficiency Virus Type 1 Neutralizing Antibody Serotyping Using Serum Pools and an Infectivity Reduction Assay. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1319-1328.	0.5	77
382	Induction of HIV Type 1 Neutralizing and <i>env</i> -CD4 Blocking Antibodies by Immunization with Genetically Engineered HIV Type 1-Like Particles Containing Unprocessed gp160 Glycoproteins. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 1187-1195.	0.5	21
383	Two Antigenically Distinct Subtypes of Human Immunodeficiency Virus Type 1: Viral Genotype Predicts Neutralization Serotype. <i>Journal of Infectious Diseases</i> , 1994, 169, 48-54.	1.9	195
384	High throughput HIV-1 microneutralization assay. <i>Protocol Exchange</i> , 0, , .	0.3	16